Journal of Vascular Surgery
Volume 45, Issue 6, Supplement , Pages A33-A38 , June 2007

Integrin αvβ3 as a target in the prevention of neointimal hyperplasia

  • Taku Kokubo, MD

      Affiliations

    • Department of Surgery, Washington University School of Medicine, St. Louis, Mo
    • ,
  • Hisashi Uchida, MD

      Affiliations

    • Department of Surgery, Washington University School of Medicine, St. Louis, Mo
    • ,
  • Eric T. Choi, MD

      Affiliations

    • Department of Surgery, Washington University School of Medicine, St. Louis, Mo
    • Department of Surgery, John Cochran Veteran’s Administration Hospital, St. Louis, Mo.
    • Corresponding Author InformationReprint requests: Eric T. Choi, MD, 660 S Euclid Ave, Campus Box 8109, St. Louis, MO 63110.

Received 18 January 2007 ,Accepted 21 February 2007.

References 

  1. Schwartz RS, Henry TD. Pathophysiology of coronary artery restenosis. Rev Cardiovasc Med. 2002;3(suppl 5):S4–S9
  2. Kotani J, Awata M, Nanto S, Uematsu M, Oshima F, Minamiguchi H, et al. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol. 2006;47:2108–2111
  3. Schwartz RS. The vessel wall reaction in restenosis. Semin Interv Cardiol. 1997;2:83–88
  4. Sarkar K, Sharma SK, Sachdeva R, Romeo F, Garza L, Mehta JL. Coronary artery restenosis: vascular biology and emerging therapeutic strategies. Expert Rev Cardiovasc Ther. 2006;4:543–556
  5. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell. 2002;110:673–687
  6. Hynes RO. Metastatic potential: generic predisposition of the primary tumor or rare, metastatic variants-or both?. Cell. 2003;113:821–823
  7. Ruoslahti E, Pierschbacher MD. Arg-Gly-Asp: a versatile cell recognition signal. Cell. 1986;44:517–518
  8. Topol EJ, Byzova TV, Plow EF. Platelet GPIIb-IIIa blockers. Lancet. 1999;353:227–231
  9. Pytela R, Pierschbacher MD, Ginsberg MH, Plow EF, Ruoslahti E. Platelet membrane glycoprotein IIb/IIIa: member of a family of Arg-Gly-Asp--specific adhesion receptors. Science. 1986;231:1559–1562
  10. Barker PL, Bullens S, Bunting S, Burdick DJ, Chan KS, Deisher T, et al. Cyclic RGD peptide analogues as antiplatelet antithrombotics. J Med Chem. 1992;35:2040–2048
  11. Liaw L, Skinner MP, Raines EW, Ross R, Cheresh DA, Schwartz SM, et al. The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins (Role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro). J Clin Invest. 1995;95:713–724
  12. Gadeau AP, Campan M, Millet D, Candresse T, Desgranges C. Osteopontin overexpression is associated with arterial smooth muscle cell proliferation in vitro. Arterioscler Thromb. 1993;13:120–125
  13. Panda D, Kundu GC, Lee BI, Peri A, Fohl D, Chackalaparampil I, et al. Potential roles of osteopontin and alphaVbeta3 integrin in the development of coronary artery restenosis after angioplasty. Proc Natl Acad Sci U S A. 1997;94:9308–9313
  14. Liaw L, Lindner V, Schwartz SM, Chambers AF, Giachelli CM. Osteopontin and beta 3 integrin are coordinately expressed in regenerating endothelium in vivo and stimulate Arg-Gly-Asp-dependent endothelial migration in vitro. Circ Res. 1995;77:665–672
  15. Brown SL, Lundgren CH, Nordt T, Fujii S. Stimulation of migration of human aortic smooth muscle cells by vitronectin: implications for atherosclerosis. Cardiovasc Res. 1994;28:1815–1820
  16. Janat MF, Argraves WS, Liau G. Regulation of vascular smooth muscle cell integrin expression by transforming growth factor beta1 and by platelet-derived growth factor-BB. J Cell Physiol. 1992;151:588–595
  17. Soldi R, Mitola S, Strasly M, Defilippi P, Tarone G, Bussolino F. Role of alphavbeta3 integrin in the activation of vascular endothelial growth factor receptor-2. Embo J. 1999;18:882–892
  18. Stromblad S, Becker JC, Yebra M, Brooks PC, Cheresh DA. Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin alphaVbeta3 during angiogenesis. J Clin Invest. 1996;98:426–433
  19. Brooks PC, Stromblad S, Sanders LC, von Schalscha TL, Aimes RT, Stetler-Stevenson WG, et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell. 1996;85:683–693
  20. Deryugina EI, Bourdon MA, Jungwirth K, Smith JW, Strongin AY. Functional activation of integrin alpha V beta 3 in tumor cells expressing membrane-type 1 matrix metalloproteinase. Int J Cancer. 2000;86:15–23
  21. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature. 1994;370:61–65
  22. Kinoh H, Sato H, Tsunezuka Y, Takino T, Kawashima A, Okada Y, et al. MT-MMP, the cell surface activator of proMMP-2 (pro-gelatinase A), is expressed with its substrate in mouse tissue during embryogenesis. J Cell Sci. 1996;109:953–959
  23. Hofmann UB, Westphal JR, Waas ET, Becker JC, Ruiter DJ, van Muijen GN. Coexpression of integrin alpha(v)beta3 and matrix metalloproteinase-2 (MMP-2) coincides with MMP-2 activation: correlation with melanoma progression. J Invest Dermatol. 2000;115:625–632
  24. Choi ET, Engel L, Callow AD, Sun S, Trachtenberg J, Santoro S, et al. Inhibition of neointimal hyperplasia by blocking alpha V beta 3 integrin with a small peptide antagonist GpenGRGDSPCA. J Vasc Surg. 1994;19:125–134
  25. Sheu JR, Wu CH, Chen YC, Hsiao G, Lin CH. Mechanisms in the inhibition of neointimal hyperplasia with triflavin in a rat model of balloon angioplasty. J Lab Clin Med. 2001;137:270–278
  26. Hoshiga M, Alpers CE, Smith LL, Giachelli CM, Schwartz SM. Alpha-v beta-3 integrin expression in normal and atherosclerotic artery. Circ Res. 1995;77:1129–1135
  27. van der Zee R, Murohara T, Passeri J, Kearney M, Cheresh DA, Isner JM. Reduced intimal thickening following alpha(v)beta3 blockade is associated with smooth muscle cell apoptosis. Cell Adhes Commun. 1998;6:371–379
  28. Srivatsa SS, Fitzpatrick LA, Tsao PW, Reilly TM, Holmes DR, Schwartz RS, et al. Selective alpha v beta 3 integrin blockade potently limits neointimal hyperplasia and lumen stenosis following deep coronary arterial stent injury: evidence for the functional importance of integrin alpha v beta 3 and osteopontin expression during neointima formation. Cardiovasc Res. 1997;36:408–428
  29. Bendeck MP, Nakada MT. The beta3 integrin antagonist m7E3 reduces matrix metalloproteinase activity and smooth muscle cell migration. J Vasc Res. 2001;38:590–599
  30. Margolin L, Fishbein I, Banai S, Golomb G, Reich R, Perez LS, et al. Metalloproteinase inhibitor attenuates neointima formation and constrictive remodeling after angioplasty in rats: augmentative effect of alpha(v)beta(3) receptor blockade. Atherosclerosis. 2002;163:269–277
  31. Matsuno H, Stassen JM, Vermylen J, Deckmyn H. Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation. Circulation. 1994;90:2203–2206
  32. Kaida T, Matsuno H, Niwa M, Kozawa O, Miyata H, Uematsu T. Antiplatelet effect of FK633, a platelet glycoprotein IIb/IIIa antagonist, on thrombus formation and vascular patency after thrombolysis in the injured hamster carotid artery. Thromb Haemost. 1997;77:562–567
  33. Bishop GG, McPherson JA, Sanders JM, Hesselbacher SE, Feldman MJ, McNamara CA, et al. Selective alpha(v)beta(3)-receptor blockade reduces macrophage infiltration and restenosis after balloon angioplasty in the atherosclerotic rabbit. Circulation. 2001;103:1906–1911
  34. Azrin MA, Ling FS, Chen Q, Pawashe A, Migliaccio F, Homer R, et al. Preparation, characterization, and evaluation of a monoclonal antibody against the rabbit platelet glycoprotein IIb/IIIa in an experimental angioplasty model. Circ Res. 1994;75:268–277
  35. Deitch JS, Williams JK, Adams MR, Fly CA, Herrington DM, Jordan RE, et al. Effects of beta3-integrin blockade (c7E3) on the response to angioplasty and intra-arterial stenting in atherosclerotic nonhuman primates. Arterioscler Thromb Vasc Biol. 1998;18:1730–1737
  36. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty (The EPIC Investigation). N Engl J Med. 1994;330:956–961
  37. Lincoff AM, Califf RM, Moliterno DJ, Ellis SG, Ducas J, Kramer JH, et al. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors (Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators). N Engl J Med. 1999;341:319–327
  38. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II (Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II). Lancet. 1997;349:1422–1428
  39. The ERASER Investigators. Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). Circulation. 1999;100:799–806
  40. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet. 1997;349:1429–1435
  41. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, et al. The EPIC Investigators Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet. 1994;343:881–886
  42. Smyth SS, Reis ED, Zhang W, Fallon JT, Gordon RE, Coller BS. Beta(3)-integrin-deficient mice but not P-selectin-deficient mice develop intimal hyperplasia after vascular injury: correlation with leukocyte recruitment to adherent platelets 1 hour after injury. Circulation. 2001;103:2501–2507
  43. Choi ET, Khan MF, Leidenfrost JE, Collins ET, Boc KP, Villa BR, et al. Beta3-integrin mediates smooth muscle cell accumulation in neointima after carotid ligation in mice. Circulation. 2004;109:1564–1569
  44. Clowes AW, Schwartz SM. Significance of quiescent smooth muscle migration in the injured rat carotid artery. Circ Res. 1985;56:139–145
  45. Carmeliet P, Moons L, Lijnen R, Janssens S, Lupu F, Collen D, et al. Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice. Circulation. 1997;96:3180–3191
  46. Peng L, Bhatia N, Parker AC, Zhu Y, Fay WP. Endogenous vitronectin and plasminogen activator inhibitor-1 promote neointima formation in murine carotid arteries. Arterioscler Thromb Vasc Biol. 2002;22:934–939
  47. Tanaka K, Sata M, Hirata Y, Nagai R. Diverse contribution of bone marrow cells to neointimal hyperplasia after mechanical vascular injuries. Circ Res. 2003;93:783–790
  48. Schwab SJ, Harrington JT, Singh A, Roher R, Shohaib SA, Perrone RD, et al. Vascular access for hemodialysis. Kidney Int. 1999;55:2078–2090
  49. Lee H, Manns B, Taub K, Ghali WA, Dean S, Johnson D, et al. Cost analysis of ongoing care of patients with end-stage renal disease: the impact of dialysis modality and dialysis access. Am J Kidney Dis. 2002;40:611–622
  50. Castier Y, Lehoux S, Hu Y, Foteinos G, Tedgui A, Xu Q. Characterization of neointima lesions associated with arteriovenous fistulas in a mouse model. Kidney Int. 2006;70:315–320

 Competition of interest: none.This research was supported in part by National Institutes of Health grant HL-68119 (E. T. C.) and by Grant-in-Aid from AHA Heartland Affiliate, Inc (E. T. C.).

PII: S0741-5214(07)00422-3

doi: 10.1016/j.jvs.2007.02.069

Journal of Vascular Surgery
Volume 45, Issue 6, Supplement , Pages A33-A38 , June 2007

Article Tools

* Image Usage & Resolution